Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6031 to 6045 of 7682 results

  1. NICE recommends further research to understand the characteristics of patients at high risk of haemostatic instability in whom viscoelastometric testing may be most cost effective.

    Recommendation ID DG13/5 Question NICE recommends further research to understand the characteristics of patients at high risk of haemostatic

    Research recommendation
    Published
    9 June 2015

  2. NICE recommends further research to validate the accuracy and precision of the My5-FU assay for the quantitative determination of 5-fluorouracil (5-FU) at the lower end of its measuring range with analytical reference standard methods, including high-performance liquid chromatography and liquid chromatography-mass spectrometry.

    Recommendation ID DG16/1 Question NICE recommends further research to validate the accuracy and precision of the My5-FU assay for the quantitative

    Research recommendation
    Published
    9 June 2015

  3. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    Recommendation ID TA293/2 Question NICE recommends research generating and analysing observational data including, but not limited to,

    Research recommendation
    Published
    9 June 2015

  4. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Recommendation ID TA161/2 Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the

    Research recommendation
    Published
    9 June 2015

  5. NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all patients having whole lymph node analysis by the RD-100i OSNA system should be submitted to this registry. These data should be integrated with data from other registries for breast cancer where appropriate.

    Recommendation ID DG8/1 Question NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system

    Research recommendation
    Published
    9 June 2015

  6. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    Recommendation ID TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts

    Research recommendation
    Published
    9 June 2015

  7. NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR-TK mutation test methods and should link to patient outcomes.

    Recommendation ID DG9/1 Question NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase

    Research recommendation
    Published
    9 June 2015

  8. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015

  10. NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital episode, with a view to informing the cost-effectiveness modelling and reducing uncertainty.

    Recommendation ID DG13/4 Question NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital

    Research recommendation
    Published
    9 June 2015

  11. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    Recommendation ID HST1/1 Question NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the

    Research recommendation
    Published
    9 June 2015

  12. NICE recommends that health economic models are developed to capture the impact of interventions on short-term outcomes such as hypoglycaemia. In addition, the feasibility of incorporating more recently developed risk prediction models for cardiovascular disease such as QRisk2 and observational data from registries such as the Swedish National Diabetes Register into health economic models for type 1 diabetes should be explored.

    Recommendation ID DG21/3 Question NICE recommends that health economic models are developed to capture the impact of interventions on short-term

    Research recommendation
    Published
    11 April 2016

  13. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    Recommendation ID TA316/1 Question NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide

    Research recommendation
    Published
    9 June 2015

  14. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin

    Research recommendation
    Published
    9 June 2015

  15. Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside nursing interventions, such as repositioning and oropharyngeal suction) better at reducing noisy respiratory secretions and patient, family and carer distress without causing unwanted side effects, than nursing interventions alone?

    Recommendation ID NG31/3 Question Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are

    Research recommendation
    Published
    27 January 2016